Trial Profile
An Exploratory Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2019
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 18 Aug 2005 New trial record.